| 1461 |
National Cancer Institute |
Html |
en |
Vaginal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of vaginal cancer. |
| ongoing clinical trials | 0.85552 |
| long time span | 0.761526 |
| vaginal carcinoma | 0.951107 |
| vaginal wall involvement | 0.883409 |
| prior hysterectomy | 0.778571 |
| vaginal cancer | 0.818887 |
| vaginal cancer. | 0.807751 |
| available staging tests | 0.778942 |
| upper vaginal lesions | 0.893311 |
| Regional lymph nodes | 0.757227 |
| concurrent chemotherapy | 0.764946 |
| clear cell carcinomas | 0.789213 |
| cervical cancer | 0.899035 |
| Vaginal adenosis | 0.826312 |
| vaginal carcinomas | 0.846251 |
| vaginal SCC patients | 0.90084 |
| treatment approaches | 0.767338 |
| women | 0.767592 |
| treatment | 0.85362 |
| AJCC staging system. | 0.759072 |
| vaginal vault | 0.831513 |
| case series | 0.90433 |
| utero DES exposure | 0.803909 |
| apical vagina | 0.754218 |
| vaginal intraepithelial neoplasia | 0.874302 |
|
| external-beam radiation | 0.754266 |
| treatment planning | 0.776769 |
| clear cell carcinoma | 0.966645 |
| clear cell adenocarcinoma | 0.790722 |
| vaginal cancers | 0.837225 |
| local modality therapies | 0.783604 |
| cervical cancer management | 0.790278 |
| noninvasive squamous cell | 0.774465 |
| relative efficacy | 0.761447 |
| Gy tumor dose | 0.754907 |
| vaginal clear cell | 0.868627 |
| disease | 0.778359 |
| precise staging criteria | 0.772344 |
| local control | 0.818953 |
| utero exposure | 0.878366 |
| Early stage tumors | 0.815533 |
| cervical intraepithelial neoplasia | 0.792254 |
| small case series | 0.758482 |
| insufficient dose penetration | 0.75402 |
| American Joint Committee | 0.782817 |
| locally advanced tumors | 0.766917 |
| Cervical Cancer Treatment | 0.817322 |
| surgical treatment options | 0.788171 |
| standard treatment | 0.795403 |
|
CLICK HERE |
| 1492 |
National Cancer Institute |
Html |
en |
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version |
For acute lymphoblastic leukemia (ALL), the 5-year survival rate rose from 60% to about 90% for children younger than 15 years and from 28% to about 75% for adolescents aged 15–19 years between 1975 and 2010. Get information about risk factors, signs, diagnosis, genomics, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL. |
| prognostic factors | 0.457078 |
| B-Cell Acute Lymphoblastic | 0.477707 |
| Cancer Statistics Review | 0.442138 |
| B-acute lymphoblastic leukemia | 0.487736 |
| Leukemia Group | 0.457445 |
| children | 0.485859 |
| childhood lymphoblastic leukaemia | 0.461366 |
| acute lymphoblastic leukaemia | 0.619966 |
| acute lymphoblastic leukemias | 0.490719 |
| leukemia cells. | 0.443609 |
| prognostic significance | 0.464566 |
| Nat Genet | 0.45804 |
| leukemia susceptibility gene | 0.452718 |
| Hyperdiploid leukemia cells | 0.447496 |
| et al. | 0.591777 |
| SEER Cancer Statistics | 0.449829 |
| lymphoblastic leukemia consortium | 0.485454 |
| childhood acute leukemias | 0.444646 |
| frank leukemia | 0.449613 |
| Br J Haematol | 0.473302 |
| early T-cell precursor | 0.46793 |
| PUBMED Abstract | 0.469887 |
| concordant leukemia | 0.449352 |
| residual leukemia | 0.447727 |
| Pediatr Blood Cancer | 0.49042 |
|
| acute lymphocytic leukemia | 0.489397 |
| Leukemia Study Group | 0.454229 |
| National Cancer Institute | 0.475056 |
| acute lymphoblastic leukaemias | 0.494907 |
| childhood leukemia | 0.453157 |
| outcome | 0.442439 |
| myeloid leukemia stem | 0.447271 |
| lymphoblastic leukemia risk | 0.49811 |
| lymphoblastic leukaemia aetiology | 0.462653 |
| childhood | 0.471724 |
| Abstract | 0.585405 |
| Acute leukaemia | 0.444978 |
| cancer group | 0.443895 |
| Pediatr Hematol Oncol | 0.438989 |
| Clin Oncol | 0.520227 |
| Pediatric Oncology Group | 0.440216 |
| infant leukemia | 0.443122 |
| acute promyelocytic leukemia | 0.469574 |
| acute lymphoblastic leukemia | 0.925289 |
| acute leukemia | 0.478163 |
| Lymphoblastic Leukemia Treated | 0.486039 |
| Children Leukemia Group | 0.457299 |
| leukemia cells | 0.45331 |
| oncology group | 0.497434 |
|
CLICK HERE |
| 1565 |
National Cancer Institute |
Html |
null |
Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lip and oral cavity cancer. |
|
|
CLICK HERE |
| 1792 |
National Cancer Institute |
Html |
es |
Náuseas y vómitos relacionados con el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las náuseas y vómitos como complicaciones del cáncer o su tratamiento. Se plantean abordajes de tratamiento de las náuseas y vómitos. |
| radioterapia nombre | 0.366149 |
| Dexametasona Corticosteroides | 0.345517 |
| palonosetrón antagonistas | 0.420992 |
| siguientes tipos | 0.357417 |
| siguientes estrategias | 0.348254 |
| único signo | 0.33198 |
| causa náuseas | 0.753796 |
| National Cancer Institute | 0.339057 |
| determinados medicamentos | 0.5578 |
| siguientes riesgos | 0.330997 |
| quimioterapia nombre | 0.555099 |
| PDQ Acupuntura | 0.392476 |
| Instituto Nacional | 0.371538 |
|
| siguientes problemas | 0.372583 |
| siguientes factores | 0.44966 |
| Physician Data Query | 0.449355 |
| Lorazepam Benzodiazepinas | 0.337793 |
| vómitos tardÃos | 0.949937 |
| siguientes caracterÃsticas | 0.461706 |
| determinadas situaciones | 0.34995 |
| fosaprepitant antagonistas | 0.342662 |
| prometazina fenotiacinas | 0.421253 |
| PDQ Náuseas | 0.567745 |
| medicamento tipo | 0.522815 |
| flujo sanguÃneo escaso | 0.412994 |
| haloperidol butirofenonas | 0.346571 |
|
CLICK HERE |
| 1827 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica. |
| genetic features predict | 0.402765 |
| Davis Z | 0.402966 |
| Exp Med | 0.403766 |
| with chronic lymphocytic | 0.453469 |
| B-cell chronic lymphocytic | 0.404152 |
| Hamblin TJ | 0.403993 |
| Montserrat E | 0.403191 |
| patients with rai | 0.4028 |
| lymphocytic leukemia reveals | 0.403683 |
| O'Brien S | 0.403439 |
| Keating MJ | 0.403308 |
| granular lymphocytes | 0.404274 |
| patients with chronic | 0.453881 |
| terapia inmediata versus | 0.402689 |
| CD38 expression | 0.404463 |
| ZAP-70 expression | 0.403246 |
| La LLC | 0.412195 |
| cell chronic lymphocytic | 0.409866 |
| Lymphocytic Leukemia updating | 0.403993 |
| patients with | 0.466989 |
| early-stage chronic lymphocytic | 0.403314 |
| gene expression | 0.402974 |
| Shanafelt TD | 0.404951 |
| International Workshop | 0.403274 |
| leukemia treated with | 0.403613 |
|
| granular lymphocyte leukemia | 0.40409 |
| versus clorambucilo | 0.403972 |
| French Cooperative Group | 0.402864 |
| monoclonal b-cell lymphocytosis | 0.404973 |
| Loughran TP Jr | 0.403102 |
| prognostic features | 0.40312 |
| leukemia with | 0.405469 |
| immunoglobulin mutation genotype | 0.402773 |
| lymphocytic leukemia from | 0.403953 |
| high-risk features such | 0.40263 |
| chronic lymphoid leukemia | 0.404328 |
| granular lymphocytic leukemia | 0.403581 |
| VH mutation status | 0.402969 |
| T-cell chronic lymphocytic | 0.403416 |
| large granular lymphocyte | 0.403546 |
| Clin Oncol | 0.457605 |
| Catovsky D | 0.410385 |
| mutation status | 0.410696 |
| chronic lymphocytic leukemia | 0.989679 |
| chronic lymphocytic leukaemia | 0.467178 |
| with chronic lymphoid | 0.403309 |
| lymphocyte leukemia with | 0.403276 |
| following chemoimmunotherapy with | 0.404045 |
| features such as | 0.402637 |
|
CLICK HERE |
| 2020 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre los factores que aumentarían el riesgo de presentar cáncer de cuello uterino y los enfoques que ayudarían a la prevención de esta enfermedad. |
| cervical intra-epithelial neoplasia | 0.302624 |
| Obstet Gynecol | 0.303555 |
| Lancet Infect Dis | 0.302739 |
| vacuna qHPV | 0.302144 |
| VPH vs | 0.303877 |
| cervical carcinoma | 0.305011 |
| cáncer invasor | 0.318393 |
| González A | 0.303459 |
| VPH oncógenos | 0.304066 |
| American Cancer Society | 0.303348 |
| case-control study | 0.30305 |
| Costa Rica Vaccine | 0.302774 |
| cervical neoplasia | 0.303702 |
| Schiffman M | 0.30246 |
| without cervical carcinoma | 0.302609 |
| risk factors | 0.303566 |
| collaborative reanalysis | 0.305986 |
| International Collaboration | 0.302415 |
| Estados Unidos | 0.303742 |
| vacuna 9vHPV | 0.303595 |
| cancer in | 0.308272 |
| Natl Cancer Inst | 0.304144 |
| cervical cancer | 0.371053 |
| vacuna vph | 0.305378 |
| North American multicohort | 0.3021 |
|
| 9-valent hpv vaccine | 0.303034 |
| VPH Población Estimación | 0.304092 |
| Quadrivalent HPV Vaccination | 0.302755 |
| human papillomavirus | 0.353991 |
| vacuna nanovalente vlp | 0.302596 |
| risk among hiv-infected | 0.30327 |
| Bosch FX | 0.30227 |
| Castle PE | 0.302445 |
| Muñoz N | 0.303856 |
| Costa Rica | 0.303541 |
| collaboration prospective study | 0.303065 |
| Immune Defic Syndr | 0.302422 |
| multicohort collaboration prospective | 0.302636 |
| Adverse Pregnancy Outcomes | 0.302449 |
| Acquir Immune Defic | 0.302422 |
| epidemiological studies | 0.313912 |
| with cervical carcinoma | 0.302983 |
| vacuna vph-16 l1 | 0.302668 |
| cervical intraepithelial neoplasia | 0.304671 |
| cuello uterino | 0.985138 |
| American multicohort collaboration | 0.302442 |
| Cancer In young | 0.302413 |
| vacuna bivalente tipo | 0.302487 |
| cancer risk | 0.305603 |
|
CLICK HERE |
| 2033 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de próstata (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad. |
| Thompson IM | 0.314327 |
| accessed july | 0.302228 |
| results from | 0.303565 |
| Connolly JM | 0.303382 |
| Prostate Cancer Events | 0.317969 |
| habitantes hombres | 0.302425 |
| Cancer Statistics Review | 0.317133 |
| Ross RK | 0.305958 |
| Sin embargo | 0.309562 |
| grasas animales | 0.30255 |
| American Cancer Society | 0.316034 |
| dietary fat | 0.303757 |
| tumores gleason | 0.303142 |
| productos lácteos | 0.302873 |
| Cancer Rates | 0.308415 |
| EI aumento | 0.303513 |
| EI riesgo | 0.304572 |
| Prostate specific | 0.303323 |
| Estados Unidos | 0.302842 |
| Natl Cancer Inst | 0.462208 |
| Gleason DF | 0.304482 |
| cancer prevention trial | 0.348935 |
| menor riesgo | 0.303815 |
| Prostate Cáncer Prevention | 0.30803 |
| SEER Cancer Statistics | 0.317438 |
|
| investigation into cancer | 0.307885 |
| Bernstein L | 0.303522 |
| prostate cancer prevention | 0.326581 |
| Prostate Prevention Trial | 0.304615 |
| Tangen CM | 0.304256 |
| Kristal AR | 0.303247 |
| EI Prostate Cancer | 0.311391 |
| United States | 0.314913 |
| Prostate Cancer Clinical | 0.31207 |
| Cancer Facts | 0.309636 |
| Kolonel LN | 0.303682 |
| prostate lncap tumors | 0.303282 |
| among japanese | 0.304198 |
| Nutr Cancer | 0.308752 |
| National Cancer Institute | 0.326849 |
| Epidemiol Biomarkers Prev | 0.307319 |
| dutasterida vs | 0.303715 |
| antecedentes familiares | 0.303019 |
| fatty acids | 0.303826 |
| Prostate Cancer Survey | 0.310986 |
| Prostate visualization studies | 0.303528 |
| grasas alimenticias | 0.316785 |
| prostate cancer | 0.996017 |
| Rose DP | 0.305512 |
|
CLICK HERE |
| 2049 |
National Cancer Institute |
Html |
es |
Trasplantes de células madre formadoras de sangre |
Hoja informativa que explica los procedimientos, paso a paso, del trasplante de médula ósea y del trasplante de células madre de sangre periférica, así como sus riesgos y beneficios. |
| células madre | 0.995824 |
| efecto gvt | 0.300369 |
| trasplante autólogo | 0.304497 |
| PBSCT alogénicos | 0.300755 |
| llamadas antÃgenos | 0.300572 |
| frecuencia células madre | 0.306001 |
| bone marrow transplantation | 0.300883 |
| raros casos | 0.300403 |
| Sin embargo | 0.307734 |
| catéter venoso central | 0.300806 |
| Programa Nacional | 0.300971 |
| llamadas células madre | 0.30624 |
| largo plazo | 0.300324 |
| causa disminución | 0.300351 |
| seguro médico | 0.300814 |
|
| cubre be | 0.300325 |
| paciente transfusiones | 0.301172 |
| HLA compatibles mejora | 0.301344 |
| idéntico. sin embargo | 0.300876 |
| antÃgenos hla | 0.303269 |
| stem cell transplantation | 0.300928 |
| programa be | 0.300461 |
| posibles efectos | 0.301054 |
| linfocitos t". | 0.3004 |
| atacan. más | 0.300461 |
| GVHD aguda | 0.300451 |
| corto plazo | 0.30031 |
| sangre. solo | 0.300435 |
| usa dosis | 0.301797 |
| tipo hla | 0.300841 |
|
CLICK HERE |
| 2973 |
National Cancer Institute |
Video |
en |
Make Sure You Have What It Takes |
Ready to quit smoking? Make sure you have what it takes. Visit teen.smokefree.gov. |
| 02 | 0.414634 |
| ElixirMediaProd | 0.414568 |
| CDC | 0.732439 |
| QuitSmokingCom | 0.418054 |
| Sperm | 0.414461 |
| Famous People | 0.497717 |
| body | 0.415775 |
| Anti Smoking Commercial | 0.594002 |
| Disease Control | 0.79595 |
| Michael | 0.432529 |
| List | 0.414915 |
| Belhus | 0.420781 |
| Story | 0.414456 |
| Ellie | 0.41667 |
| Smokers | 0.569726 |
| Asthma Attack | 0.474832 |
| Duration | 0.939681 |
| Home Alchemy | 0.475983 |
| Hollywood | 0.417592 |
| mutation | 0.414755 |
| Smoking Advice | 0.525781 |
| Men | 0.414403 |
| Unattractive Things | 0.479984 |
| basement | 0.414589 |
|
| Smoking Timeline | 0.544895 |
| Centers | 0.483728 |
| NHS Smokefree | 0.484439 |
| Allen Carr | 0.481427 |
| Unkle Adams | 0.494687 |
| Losers Game | 0.480152 |
| air | 0.41576 |
| Aadarsh Sharma | 0.493771 |
| Videos | 0.414563 |
| Prevention | 0.483581 |
| Chicken Egg | 0.47424 |
| Great Ads | 0.480844 |
| smoking | 0.667373 |
| Smoking PSA | 0.536443 |
| views | 0.800457 |
| Terrifying | 0.418131 |
| CDC Tips | 0.549794 |
| James | 0.414466 |
| Domonic Smith | 0.486979 |
| Quit Smoking | 0.543911 |
| COPD patient | 0.483677 |
| Olly | 0.42117 |
| Planet Nibiru | 0.480348 |
| Doritos Commercial Compilation | 0.548737 |
|
CLICK HERE |
| 4389 |
National Cancer Institute |
Html |
en |
Sunlight |
Exposure to UV radiation from the sun, sunlamps, and tanning booths causes early aging and skin damage that can lead to skin cancer. Find information, including tips, on how to protect your skin. |
| skin cancer | 0.670141 |
| sun visors | 0.456822 |
| shades | 0.330644 |
| early aging | 0.476035 |
| dark skin | 0.458278 |
| sources | 0.329654 |
| skin damage | 0.480277 |
| wide brim | 0.466856 |
| windshields | 0.391235 |
| mid-morning | 0.329734 |
| long pants | 0.452301 |
| skin | 0.754109 |
| SPF | 0.373931 |
| ice | 0.356895 |
| UPF | 0.341366 |
| clouds | 0.329163 |
| skin tones | 0.597399 |
| tips | 0.329364 |
| Wear sunglasses | 0.448638 |
| sun protection factor | 0.555629 |
| dark fabrics | 0.445529 |
| light skin tone | 0.592307 |
| hat | 0.32822 |
|
| pavement | 0.327954 |
| mind | 0.357411 |
| late afternoon | 0.469796 |
| light clothing | 0.439637 |
| Exposure | 0.331467 |
| sunscreen products | 0.456996 |
| windows | 0.357118 |
| neck | 0.328307 |
| people | 0.384721 |
| water | 0.356986 |
| UV radiation | 0.940101 |
| sand | 0.362057 |
| sunlight | 0.380409 |
| ultraviolet protection factor | 0.576115 |
| snow | 0.359149 |
| booths | 0.335732 |
| parts | 0.327951 |
| ages | 0.329914 |
| sunlamps | 0.332236 |
| time | 0.329824 |
| beds | 0.330757 |
| rays | 0.330102 |
|
CLICK HERE |